T-cell activation involves two phases, enabling a more precise immune response. This insight may boost cancer immunotherapy ...

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and ...

We’re building a new immune response.” —Grégoire Altan-Bonnet, National Institutes of Health He and his lab first engineered CAR T cells to produce IL-2, an immune-boosting cytokine known to stimulate ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

A team from the Max Planck Research Group for Systems Immunology at the University of Würzburg has identified a previously unknown phase of the immune response. The results, published in Science, ...

Coya Therapeutics (COYA) announced interim results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and ...

LD IL-2 preferentially binds the IL-2 receptor alpha ... on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation.

CD4+ and CD8+ T cells accumulate in the skin of patients with psoriasis. These cells are also identified by markers of activation (e.g., increased IL-2 receptors and HLA-DR surface molecules ...